Cytosorbents Corporation (NASDAQ:CTSO)‘s stock had its “buy” rating restated by investment analysts at B. Riley in a research report issued to clients and investors on Monday. They currently have a $11.25 price target on the medical research company’s stock. B. Riley’s target price points to a potential upside of 136.84% from the stock’s previous close.

A number of other research analysts also recently weighed in on CTSO. Maxim Group reissued a “buy” rating and issued a $10.00 price target on shares of Cytosorbents Corporation in a research note on Wednesday, April 19th. Aegis reissued a “buy” rating and issued a $9.00 price target on shares of Cytosorbents Corporation in a research note on Tuesday, May 9th. Finally, Cowen and Company initiated coverage on Cytosorbents Corporation in a research note on Wednesday, June 7th. They issued an “outperform” rating and a $7.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, Cytosorbents Corporation currently has a consensus rating of “Buy” and an average target price of $12.38.

Cytosorbents Corporation (CTSO) traded up 3.26% during mid-day trading on Monday, hitting $4.75. The stock had a trading volume of 163,008 shares. The stock has a 50 day moving average of $4.53 and a 200-day moving average of $4.90. The firm’s market cap is $133.51 million. Cytosorbents Corporation has a 1-year low of $3.30 and a 1-year high of $6.90.

Cytosorbents Corporation (NASDAQ:CTSO) last announced its quarterly earnings data on Monday, May 8th. The medical research company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.06. The firm had revenue of $3.11 million for the quarter, compared to analyst estimates of $2.99 million. Cytosorbents Corporation had a negative return on equity of 1,426.21% and a negative net margin of 108.69%. Analysts predict that Cytosorbents Corporation will post ($0.29) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/07/cytosorbents-corporation-ctso-receives-buy-rating-from-b-riley.html.

In other Cytosorbents Corporation news, insider Phillip P. Chan purchased 6,300 shares of the company’s stock in a transaction dated Monday, June 5th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $25,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders bought 17,500 shares of company stock valued at $70,620. 5.60% of the stock is owned by company insiders.

Several large investors have recently added to or reduced their stakes in the stock. Segantii Capital Management Ltd increased its stake in Cytosorbents Corporation by 563.4% in the first quarter. Segantii Capital Management Ltd now owns 27,200 shares of the medical research company’s stock worth $122,000 after buying an additional 23,100 shares during the last quarter. Cowen Group Inc. acquired a new stake in Cytosorbents Corporation during the first quarter worth $248,000. Sabby Management LLC acquired a new stake in Cytosorbents Corporation during the first quarter worth $990,000. Skylands Capital LLC increased its stake in Cytosorbents Corporation by 1,276.5% in the first quarter. Skylands Capital LLC now owns 316,600 shares of the medical research company’s stock worth $1,425,000 after buying an additional 293,600 shares during the last quarter. Finally, Advisor Group Inc. increased its stake in Cytosorbents Corporation by 1.1% in the third quarter. Advisor Group Inc. now owns 305,145 shares of the medical research company’s stock worth $1,953,000 after buying an additional 3,300 shares during the last quarter. Institutional investors own 9.74% of the company’s stock.

Cytosorbents Corporation Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents Corporation (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.